Influenza A Infections Market is segmented By Therapeutic Product (Prophylactic treatments, Antivira...
Market Size in USD Mn
CAGR2.9%
Study Period | 2025-2032 |
Base Year of Estimation | 2024 |
CAGR | 2.9% |
Market Concentration | Medium |
Major Players | Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology and Among Others |
The influenza A infections market is estimated to be valued at USD 744.2 Mn in 2025 and is expected to reach USD 909.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 2.9% from 2025 to 2032. Widespread initiatives by governments and private organizations to increase vaccination rates along with rising awareness about preventive healthcare have contributed to the market growth.